Chemistry:STAC-9

From HandWiki
Short description: Organic compound, experimental pharmaceutical
STAC-9
STAC-9 structure.png
Identifiers
PubChem CID
UNII
Chemical and physical data
FormulaC20H15F3N4O
Molar mass384.362 g·mol−1
3D model (JSmol)

STAC-9 is an experimental drug that was developed by GlaxoSmithKline as a small-molecule activator of the sirtuin subtype SIRT1, with potential applications in the treatment of diabetes.[1][2][3]

See also

References

  1. Ng PY, Blum C, Mcpherson L, Perni RB, Vu CB, Ahmed MM, Disch JS, "Bicyclic pyridines and analogs as sirtuin modulators.", US patent 9556201, published 4 October 2012, assigned to Sitris Pharmaceuticalsand GlaxoSmithKline
  2. "Evidence for a common mechanism of SIRT1 regulation by allosteric activators". Science 339 (6124): 1216–9. March 2013. doi:10.1126/science.1231097. PMID 23471411. Bibcode2013Sci...339.1216H. 
  3. "Emerging drugs affecting skeletal muscle function and mitochondrial biogenesis - Potential implications for sports drug testing programs". Rapid Communications in Mass Spectrometry 30 (5): 635–51. March 2016. doi:10.1002/rcm.7470. PMID 26842585. Bibcode2016RCMS...30..635T.